Company intelligence / Profile preview

Biotoxtech

Cheongju-si, Chungcheongbuk-do, South Koreaeng.biotoxtech.com ↗

Ownership: Public · A086040
Employees: ~250
Development stage: Commercial

01

Overview

Leading Korean non-clinical CRO specializing in safety/toxicology evaluations

Therapeutic areas: GastroenterologyOphthalmologyPulmonology
Modalities: Small molecule drugsRecombinant polypeptidesCell therapeutics (testing services)Medical devices and chemicals (testing services)
Industry: Contract Research Organization

02

Financials

Market cap: $29.3B
Total revenue: $6.5B
Enterprise value: $45.1B

Beyond the preview

Go deeper on Biotoxtech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Biotoxtech.